Published in Acta Crystallogr Sect F Struct Biol Cryst Commun on April 30, 2008
Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. Sci Rep (2013) 1.02
Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies. Sci Rep (2015) 0.83
Crystallization and preliminary X-ray diffraction analysis of the Fab portion of the Alzheimer's disease immunotherapy candidate bapineuzumab complexed with amyloid-β. Acta Crystallogr F Struct Biol Commun (2014) 0.80
mCSM-AB: a web server for predicting antibody-antigen affinity changes upon mutation with graph-based signatures. Nucleic Acids Res (2016) 0.79
Deletion of the type-1 interferon receptor in APPSWE/PS1ΔE9 mice preserves cognitive function and alters glial phenotype. Acta Neuropathol Commun (2016) 0.79
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature (1987) 17.08
Alzheimer's disease is a synaptic failure. Science (2002) 13.82
Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem (1996) 3.10
Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem (1998) 2.78
Screening and optimization strategies for macromolecular crystal growth. Acta Crystallogr D Biol Crystallogr (1994) 2.62
Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope. J Mol Biol (2008) 1.17
Amyloid-beta peptide disruption of lipid membranes and the effect of metal ions. J Mol Biol (2005) 1.12
Solution structure of methionine-oxidized amyloid beta-peptide (1-40). Does oxidation affect conformational switching? Biochemistry (1998) 1.08
Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease. Cell Mol Life Sci (2006) 1.07
Solution structure of amyloid beta-peptide (25-35) in different media. J Med Chem (2004) 1.04
The molecular link between beta- and gamma-secretase activity on the amyloid beta precursor protein. Cell Mol Life Sci (2007) 0.98
Solution structures in aqueous SDS micelles of two amyloid beta peptides of A beta(1-28) mutated at the alpha-secretase cleavage site (K16E, K16F). J Struct Biol (2000) 0.87
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain (2007) 6.39
Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov (2004) 5.82
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol (2013) 5.73
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging (2010) 5.49
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A (2005) 4.34
Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol (2008) 3.67
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol (2003) 3.58
Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol (2010) 3.46
Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med (2012) 3.31
Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol (2002) 3.30
Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol (2012) 3.03
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol (2008) 3.03
A primer of amyloid nomenclature. Amyloid (2007) 2.70
Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell (2010) 2.46
Siah ubiquitin ligase is structurally related to TRAF and modulates TNF-alpha signaling. Nat Struct Biol (2002) 2.32
Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron (2008) 2.30
Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target? Acta Neuropathol (2014) 2.25
AMPK beta subunit targets metabolic stress sensing to glycogen. Curr Biol (2003) 2.19
Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid (2005) 2.14
Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem (2002) 1.99
Homo- and heterodimerization of APP family members promotes intercellular adhesion. EMBO J (2005) 1.98
C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. Hum Mol Genet (2006) 1.97
A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. Biochemistry (2002) 1.93
Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein. J Immunol (2005) 1.92
Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet (2003) 1.91
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) (2012) 1.90
Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity. J Neurosci (2008) 1.86
Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol (2005) 1.83
The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell (2008) 1.83
Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci (2005) 1.83
The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim Biophys Acta (2007) 1.83
In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. Eur J Nucl Med Mol Imaging (2014) 1.80
Elucidation of the substrate binding site of Siah ubiquitin ligase. Structure (2006) 1.79
Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol (2002) 1.79
Anxiety over GABA(A) receptor structure relieved by AChBP. Trends Biochem Sci (2002) 1.74
Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem (2002) 1.74
Critical role for the second extracellular loop in the binding of both orthosteric and allosteric G protein-coupled receptor ligands. J Biol Chem (2007) 1.70
mCSM: predicting the effects of mutations in proteins using graph-based signatures. Bioinformatics (2013) 1.69
18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain (2011) 1.67
PrPC-related signal transduction is influenced by copper, membrane integrity and the alpha cleavage site. Cell Res (2009) 1.64
The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood (2009) 1.63
The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves alpha-, beta-, gamma-, and epsilon-like cleavages: modulation of APLP-1 processing by n-glycosylation. J Biol Chem (2004) 1.63
Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry (2006) 1.63
Insights into the action of the superfamily of cholesterol-dependent cytolysins from studies of intermedilysin. Proc Natl Acad Sci U S A (2005) 1.63
Dopamine D2 receptor knockout mice develop features of Parkinson disease. Ann Neurol (2009) 1.62
Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. Neuropsychologia (2011) 1.62
Cytoplasmic ATP-sensing domains regulate gating of skeletal muscle ClC-1 chloride channels. J Biol Chem (2005) 1.62
Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med (2007) 1.60
Amyloid fibril protein nomenclature -- 2002. Amyloid (2002) 1.59
Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain (2012) 1.58
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 1.58
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis (2010) 1.57
Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS One (2007) 1.55
Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med (2011) 1.54
Structures of perfringolysin O suggest a pathway for activation of cholesterol-dependent cytolysins. J Mol Biol (2007) 1.54
Genetic algorithm with logistic regression for prediction of progression to Alzheimer's disease. BMC Bioinformatics (2014) 1.53
Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J Neurosci (2002) 1.52
Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. FASEB J (2008) 1.52
In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci (2007) 1.52
Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J (2005) 1.51
Structural basis for glycogen recognition by AMP-activated protein kinase. Structure (2005) 1.50
Plasma amyloid beta42 and amyloid beta40 levels are associated with early cognitive dysfunction after cardiac surgery. Ann Thorac Surg (2009) 1.50
The role of exosomes in the processing of proteins associated with neurodegenerative diseases. Eur Biophys J (2007) 1.50
Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian imaging, biomarkers and lifestyle (AIBL) study of ageing. Int Psychogeriatr (2011) 1.49